<div id="readability-page-1"><p>Anika Therapeutics, Inc. ((ANIK)) has held its Q4 earnings call. Read on for the main highlights of the call.</p><h3>Claim 70% Off TipRanks Premium</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  and maximize your portfolio's potential</li></ul> <p>Anika Therapeutics’ latest earnings call painted a cautiously optimistic picture, balancing clear commercial momentum and bottom-line progress against lingering revenue pressure, regulatory setbacks and OEM pricing headwinds. Management stressed improved execution, margin recovery in the fourth quarter and a credible path to stronger profitability, even as they acknowledged material challenges that will test the company’s ability to deliver in 2026 and beyond.</p> <h2>Commercial Channel Growth</h2> <p>Commercial channel sales were the key bright spot, climbing 22% in Q4 to $13.3 million and rising 15% for the full year to $48.4 million. Management credited international osteoarthritis pain franchises and accelerating adoption of the Integrity implant as the primary engines of this growth, underscoring a strategic shift toward higher-value commercial revenue.</p> <h2>International OA Pain Momentum</h2> <p>International osteoarthritis pain revenue surged 28% in Q4 and increased 12% for the year, with Monovisc, Orthovisc and Cingal gaining share across several markets. Executives highlighted a lean commercial and supply chain setup that they believe can sustain double-digit growth, positioning these products as a counterweight to domestic OEM pricing pressure.</p> <h2>Integrity Commercial Traction</h2> <p>Integrity, Anika’s rotator cuff repair solution, continued to gain momentum, with procedures and revenue more than doubling in 2025 to roughly $6 million. Since launch, more than 2,500 surgeries have used the product, over 300 surgeons are now active users and nearly 600 procedures were performed in Q4 alone, marking the seventh straight quarter of sequential growth.</p> <h2>Operational and Margin Improvement</h2> <p>Operational execution improved notably in the fourth quarter, with GAAP gross margin expanding to 63%, up from 56% a year earlier. Management pointed to better manufacturing productivity, higher throughput and operating leverage from increased volumes, translating into positive operating income and laying a foundation for future profitability gains.</p> <h2>Improved Profitability (Adjusted EBITDA)</h2> <p>Adjusted EBITDA from continuing operations reached $4.5 million in Q4 and $5.3 million for 2025, equating to roughly 5% of revenue. This performance topped the company’s revised outlook, which had anticipated a range from slightly negative to modestly positive, signaling tighter cost control and improved business mix.</p> <h2>Stronger Cash Generation and Balance Sheet</h2> <p>Cash generation strengthened as operating cash flow rose to $11.2 million in 2025, more than double the prior year’s $5.4 million. Anika ended the year with $57.5 million in cash and no debt, after funding $6.8 million of capital expenditures and executing the bulk of a $15 million share repurchase program, underscoring balance-sheet flexibility.</p> <h2>Total Revenue Flat and Full-Year Decline</h2> <p>Despite the progress in key segments, top-line performance remained under pressure, with Q4 revenue essentially flat year over year at $30.6 million. For the full year, revenue declined 6% to $112.8 million, in line with revised guidance but highlighting that growth in the commercial channel was not yet enough to offset OEM weakness and other headwinds.</p> <h2>OEM Channel Headwinds and Pricing Pressure</h2> <p>The OEM channel continued to drag results, with revenue down 12% in Q4 to $17.3 million and off 17% for the year at $64.4 million. Management cited lower pricing in the U.S. osteoarthritis pain market through its J&amp;J MedTech partnership as the primary culprit, noting that unit demand and market leadership remained intact but pricing pressure compressed revenue.</p> <h2>Hyalofast Clinical and Regulatory Setback</h2> <p>The company faced a setback with Hyalofast as the FastTRACK Phase III trial failed to hit its pre-specified co-primary endpoints. In early 2026, regulators issued a deficiency letter on the PMA filing covering both clinical and manufacturing data, creating fresh uncertainty around the program’s path forward and adding regulatory risk to the pipeline.</p> <h2>Full-Year Gross Margin Contraction</h2> <p>While Q4 margin trends were encouraging, Anika’s full-year GAAP gross margin slipped to 57% from 63% in 2024. The company pointed to unfavorable product mix, earlier manufacturing disruptions and costs tied to legacy programs as the main drivers, indicating that sustained margin recovery will depend on continued volume growth and portfolio shift.</p> <h2>Regulatory and Timeline Uncertainty for Cingal</h2> <p>Cingal advanced through toxicity testing in 2025 and entered a bioequivalence study in December, with planned enrollment of just under 60 patients. However, management emphasized that the timing of a potential U.S. regulatory submission remains uncertain and depends on completing enrollment and generating the necessary data, adding another variable to the long-term growth story.</p> <h2>Organizational Transitions and Cost Actions</h2> <p>To support margin expansion, Anika is implementing cost actions, including leadership role eliminations and leveling changes expected to deliver about $2.5 million in annual headcount savings and more than $3 million in stock-based compensation reduction. These moves come alongside senior leadership departures and unfilled C-suite roles, which could create near-term execution risk even as they lower overhead.</p> <h2>Forward-Looking Guidance and Outlook</h2> <p>For 2026, Anika reiterated total revenue guidance of $114 million to $122.5 million, implying 1% to 9% growth, with commercial revenue targeted to rise 10% to 20% and OEM sales projected to be flat to down 5%. Adjusted EBITDA is expected to improve to 5% to 10% of revenue, supported by commercial momentum, manufacturing gains and general and administrative cost cuts, while free cash flow should roughly match last year’s operating cash generation.</p> <p>Anika’s earnings call delivered a mixed but improving narrative, with strong commercial traction, better cash generation and Q4 margin recovery offset by OEM pricing pressure and regulatory setbacks for key pipeline assets. Investors will be watching closely to see whether management can sustain commercial growth, navigate regulatory hurdles and turn the initial profitability progress into durable earnings expansion over the next two years.</p></div>

ANIK

<p>Anika Therapeutics, Inc. reported a cautiously optimistic Q4 earnings call, highlighting a 22% increase in commercial channel sales to $13.3 million. Despite a flat Q4 revenue of $30.6 million and a 6% decline for the year, operational improvements led to a GAAP gross margin of 63%. Adjusted EBITDA reached $4.5 million in Q4. However, the OEM channel faced challenges, with a 12% revenue drop. Regulatory setbacks with Hyalofast and uncertainty around Cingal's timeline add to the company's challenges, while cost-cutting measures aim to enhance profitability.</p>

Anika Therapeutics Earnings Call Signals Cautious Rebound